A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

This is a Phase II, open-label, nonrandomized, single-arm study of elranatamab that will be administered in the outpatient setting in 2 sequential cohorts of participants with relapsed or refractory multiple myeloma (RRMM). The primary objective of this study is to evaluate the overall incidence of cytokine release syndrome (CRS) during Cycle 1 of elranatamab treatment following a single prophylactic dose of tocilizumab.

Trial Details

NCT ID
NCT07637578
Phase
PHASE2
Sponsor
SCRI Development Innovations, LLC
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Elranatamab
  • Tocilizumab
Locations (sample)
  • Denver, Colorado, United States|39.73915,-104.9847
  • Denver, Colorado, United States|39.73915,-104.9847
  • Columbia, Maryland, United States|39.24038,-76.83942
  • Eugene, Oregon, United States|44.05207,-123.08675
  • Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

  • Written informed consent, according to institutional guidelines, signed and dated by the participant or by a legal guardian prior to the performanc…
  • At least 18 years-of-age at the time of signature of the ICF
  • Has documented diagnosis of MM according to IMWG diagnostic criteria
  • Measurable disease at screening, as assessed by local laboratory, defined by any of the following:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →